Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Anavex Life Sciences Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.755 for today's call. At this time, all participants are in a listen-only mode. 00:00:04.755 -- 00:00:08.499 Later, we will conduct a question and answer session, and during the session, if you'd 00:00:08.499 -- 00:00:12.543 like to ask a question, please use the Q&A box or raise your hand. 00:00:12.543 -- 00:00:16.586 Please note this conference is being recorded, and the call will be available for replay 00:00:16.586 -- 00:00:20.608 on Anavex's website at www.anavex.com. 00:00:21.691 -- 00:00:26.496 With us today is Dr. Christopher Misling, President and Chief Executive Officer, and 00:00:26.496 -- 00:00:29.883 Sandra Burnish, Principal Financial Officer. 00:00:29.883 -- 00:00:33.087 Before we begin, please note that during this conference call, the company will make 00:00:33.087 -- 00:00:35.531 some projections and forward-looking statements. 00:00:35.531 -- 00:00:40.277 These statements are only predictions based on the current information and expectations 00:00:40.277 -- 00:00:43.261 and involve a number of risks and uncertainties. 00:00:43.261 -- 00:00:46.505 We encourage you to review the company's filings with the SEC. 00:00:46.505 -- 00:00:51.612 This includes, without limitation, the company's forms 10-K and 10-Q, which identify 00:00:51.612 -- 00:00:57.200 the specific factors that may cause actual results or events to differ materially 00:00:57.200 -- 00:01:00.494 from those described in these forward-looking statements. 00:01:00.494 -- 00:01:04.360 These factors may include, without limitation, risks inherent in the development and 00:01:04.360 -- 00:01:09.307 or commercialization of potential products, uncertainty in the results of clinical trials 00:01:09.307 -- 00:01:14.215 or regulatory approvals, need and ability to o...